ArticlePharmaceutical research2009
Quantitative dynamic models of arthritis progression in the rat.
Article in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.Pharmaceutics · 2024Review
- The relationship between gender and pharmacology.Current research in pharmacology and drug discovery · 2024Article
- Article
- Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?Pharmaceuticals (Basel, Switzerland) · 2023Review
- Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases.Pharmaceutics · 2022Article
- Comparative Assessment of the New PDE7 Inhibitor - GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach.Pharmaceutical research · 2020Article
- Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats.Pharmaceutical research · 2018Article
- Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics.The Journal of pharmacology and experimental therapeutics · 2017Article
- Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.Clinical pharmacology and therapeutics · 2017Article
- Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis.Arthritis research & therapy · 2017Article
- A quantitative mechanistic PK/PD model directly connects Btk target engagement andChemical science · 2017Article
- Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats.Pharmacology research & perspectives · 2015Article
- Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms.CPT: pharmacometrics & systems pharmacology · 2014Article
- Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods.CPT: pharmacometrics & systems pharmacology · 2014Article
- Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- Pharmacokinetic/pharmacodynamic modeling in inflammation.Critical reviews in biomedical engineering · 2012Review
- Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.Journal of pharmacokinetics and pharmacodynamics · 2011Article
- Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.Pharmaceutical research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeThis comparison employs mathematical disease progression models to identify a rat model of arthritis with the least inter-animal variability and features lending to better study designs.
methodsArthritis was induced with either collagen (CIA) or mycobacterium (AIA) in either Lewis or Dark Agouti (DA) rats. Disease progression was monitored by paw edema and body weight. Models with production, loss, and feedback components were constructed and population analysis using NONMEM software was employed to identify inter-animal variability in the various disease progression parameters.
resultsOnset time was the only parameter different within all four groups (DA-AIA 11.5 days, DA-CIA 16.5 days, Lewis-AIA 11.9 days, Lewis-CIA 13.9 days). The loss-of-edema rate constant was 20% slower in DA (0.362 h(-1)) than Lewis (0.466 h(-1)) rats. Most models exhibited peak paw edema 20 days post-induction. Edema in CIA returned to 150% of the initial value after the disease peaked. DA rats displayed more severe overall responses.
conclusionsNo statistical differences between groups were observed for inter-animal variation in disease onset, progression and severity parameters. Onset time varies and should be noted in the design of future studies. DA rats may offer a more dynamic range of edema response than Lewis rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.